Yale University
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.
This is an open-label, Phase 2 study designed to assess the clinical activity of sacituzumab govitecan in subjects with recurrent or persistent cervical cancer.
Inclusion Criteria: * Patients must have radiologically confirmed (i.e., CAT scan and/or MRI) persistent or recurrent histologically confirmed cervical cancer of epithelial origin who have progressed following at least one prior chemotherapy treatment regimen. * Must have availability of archival tumor tissue FFPE block for TROP-2 testing * Chemotherapy administered concurrent with primary radiation (i.e., weekly cisplatin) is not counted as a systemic chemotherapeutic regimen for management of persistent or recurrent carcinoma of the cervix. * All patients must have measurable disease.…
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).
Arctuva estimate
Verify or correct the compensation shown for this listing.